Case Overview

A five-year patent infringement battle over assembly monitoring technology came to a quiet but definitive close in April 2024, when Wildcat Licensing Wi, LLC and Bayerische Motoren Werke AG — along with its U.S. affiliates — agreed to dismiss all claims with prejudice before reaching a trial verdict. Filed in the Delaware District Court on May 6, 2019, the case centered on two reissued U.S. patents directed at systems and methods for monitoring proper fastening of assembly articles at multiple locations — technology with direct relevance to automotive manufacturing quality control.

The resolution, entered pursuant to Rule 41 of the Federal Rules of Civil Procedure, left each party responsible for its own attorneys’ fees and costs, signaling a negotiated exit rather than a decisive courtroom outcome. For patent attorneys, IP professionals, and R&D teams operating in the automotive and industrial assembly sectors, this case offers meaningful insights into patent assertion lifecycle management, reissued patent strategy, and the litigation economics of pursuing or defending assembly process patents against major automotive manufacturers.

The Parties

The Patents at Issue

Two reissued patents were asserted in this litigation:

• • U.S. Patent RE47,220 (Application No. 15/425,946)
• • U.S. Patent RE47,232 (Application No. 15/452,306)

Both patents relate to systems and methods for **monitoring proper fastening of an article of assembly at more than one location** — a technology class directly applicable to precision manufacturing environments such as automotive assembly lines where bolt torque, fastener placement, and multi-point verification are critical quality-control operations.

Reissued patents are significant because they have undergone USPTO correction proceedings, often to broaden or clarify original claim scope — a factor that typically intensifies validity scrutiny during litigation.

Legal Representation

• • Plaintiff’s Counsel: Stephen B. Brauerman of Bayard PA (Delaware)
• • Defendant’s Counsel: Brian A. Biggs of DLA Piper US LLP

Delaware-based Bayard PA is a recognized local counsel firm in patent litigation matters, while DLA Piper provides BMW with the full-scale resources of one of the world’s largest global law firms.

Litigation Timeline & Procedural History

The complaint was filed on **May 6, 2019**, in the **U.S. District Court for the District of Delaware** — the nation’s most frequently selected venue for patent infringement litigation, favored for its experienced judiciary, well-developed patent case law, and efficient case management.

The case remained active at the first-instance (district court) trial level throughout its duration, spanning approximately **five years** before the Stipulation of Dismissal was filed and the case closed on **April 17, 2024**.

The extended timeline — common in complex patent disputes involving multiple defendants, reissued patents, and manufacturing-process claims — likely encompassed standard Delaware District Court milestones: initial pleadings and motions to dismiss, scheduling orders, fact discovery, expert discovery, claim construction (Markman) proceedings, and potentially dispositive motion practice.

No chief judge was assigned on record, and the specific intermediate rulings and procedural milestones were not publicly detailed in the available case data. The five-year duration itself, however, suggests substantive litigation activity preceded the parties’ mutual decision to resolve the matter without trial.

The Verdict & Legal Analysis

Outcome

The case was **dismissed with prejudice** via a joint Stipulation of Dismissal signed by all appearing parties, submitted pursuant to **Rule 41 of the Federal Rules of Civil Procedure**. Critically, the stipulation specifies that:

• • All claims asserted by Wildcat Licensing Wi against the BMW defendants are dismissed with prejudice
• • All counterclaims asserted by the BMW defendants against Wildcat are similarly dismissed with prejudice
• • Each party bears its own attorneys’ fees, costs, and expenses

No damages award, royalty determination, or injunctive relief was entered. The mutual fee-bearing structure — where neither party recovers costs — is a hallmark of negotiated settlement exits rather than court-ordered resolutions.

Verdict Cause Analysis

The underlying cause of action was a standard **patent infringement action**. The assertion of *reissued* patents (RE47,220 and RE47,232) introduces a distinctive legal dimension: reissued patents are subject to the **doctrine of intervening rights**, which can limit the enforceability of reissued claims against products made, used, or sold before the reissue date. BMW’s defense team at DLA Piper would predictably have explored this doctrine alongside traditional invalidity arguments — including obviousness, prior art challenges, and the adequacy of the reissue proceedings themselves.

The accused products — an **assembly system** and **method for monitoring proper fastening at more than one location** — implicate BMW’s manufacturing processes directly, which raises the litigation stakes considerably: process patent assertions against an automaker’s assembly line can threaten operational continuity at scale, not merely product sales.

Legal Significance

While the dismissal with prejudice precludes Wildcat from re-asserting these specific patents against these specific BMW entities, the case does not generate published claim construction rulings or precedential invalidity findings. This outcome is legally significant in what it *does not produce*: no Markman order interpreting the fastening-system claims, and no adjudicated invalidity determination that could be used in subsequent proceedings against other defendants.

For the reissued patent community, this is a notable data point: both RE47,220 and RE47,232 exit this litigation without a court-issued validity determination, leaving their claim scope legally untested in the public record.

Strategic Takeaways

For Patent Holders (NPEs and Innovators):

Asserting reissued patents against major automotive manufacturers requires careful pre-litigation analysis of intervening rights exposure. A five-year litigation without adjudicated resolution suggests that both claim strength and settlement economics drove strategy throughout. Early licensing outreach — before costly multi-year litigation — may yield more efficient monetization.

For Accused Infringers:

BMW’s multi-entity defense (AG, Manufacturing Co., and North America LLC) reflects standard practice to ensure complete coverage across corporate affiliates. Mutual dismissal with each party bearing its own fees suggests BMW avoided an adverse fee-shifting outcome under 35 U.S.C. § 285 — a favorable defensive result.

For R&D and Manufacturing Teams:

Freedom-to-operate (FTO) analysis for assembly monitoring systems should account for the active reissued patent family in this space. Although these patents are now resolved against BMW, they remain issued patents that may be asserted against other manufacturers.

Industry & Competitive Implications

The automotive manufacturing sector is a recurring target for assembly-process patent assertions, given the complexity and scale of modern production lines. Systems that monitor fastening integrity across multiple assembly points — whether through torque sensing, electronic verification, or integrated quality-control platforms — represent critical infrastructure in vehicle manufacturing.

For companies developing or deploying smart assembly monitoring systems, this case underscores several market realities. First, NPE assertion activity in manufacturing-process patents remains active and capable of sustaining multi-year litigation against well-resourced defendants. Second, the reissued patent vehicle continues to be a tool for claim-scope refinement ahead of assertion campaigns. Third, the automotive industry’s deep litigation resources enable extended defense strategies that may outlast an NPE’s economic tolerance for protracted disputes.

Licensing professionals should note that the mutual dismissal structure — with no disclosed settlement payment — may reflect either a cross-license arrangement with confidential terms, a walk-away driven by weakened claim positions, or a strategic decision tied to broader portfolio considerations not visible in the public docket.